Journal: Clinics

Article Title: Mesenchymal stem cells in lung diseases and their potential use in COVID-19 ARDS: A systematized review

doi: 10.1016/j.clinsp.2023.100237

Figure Lengend Snippet: Narrative reviews on the administration of ASCs in chronic or acute lung diseases.

Article Snippet: Autologous Adipose-derived Stem Cells (AdMSCs) for COVID-19 (2020) , • Phase II randomized, double-blind, placebo-control study conducted in multiple clinic facilities , • 200 participants (> 18 years; male or female; have banked AdMSCs in Celltex; written informed consent; highly susceptible to SARS-CoV-2 infections, no terminal stages; no previous COVID-19 history, SARS-CoV-2 RT-PCR or equivalent tests negative; SARS-CoV-2 IgM and IgG negative) , • Three doses of 200 million autologous adipose derived mesenchymal stem cells via intravenously infusion every three days , • Three doses of placebo via intravenously infusion every three days. , • Primary outcomes: Assessment of the total number of AEs/SAEs related and non-related with the medication [Time Frame: 6 months]; Proportion of AEs/SAEs related and non-related with the ASCs infusions as compared to the control group [Time Frame: 6 months]; COVID-19 incidence rates [Time Frame: 6 months] , Not yet recruiting.

Techniques: Histopathology, Immunohistochemistry, Clinical Proteomics, Derivative Assay, Genetically Modified, Activity Assay, Generated

Journal: Clinics

Article Title: Mesenchymal stem cells in lung diseases and their potential use in COVID-19 ARDS: A systematized review

doi: 10.1016/j.clinsp.2023.100237

Figure Lengend Snippet: Published clinical trials on the administration of ASCs in chronic or acute lung diseases.

Article Snippet: Autologous Adipose-derived Stem Cells (AdMSCs) for COVID-19 (2020) , • Phase II randomized, double-blind, placebo-control study conducted in multiple clinic facilities , • 200 participants (> 18 years; male or female; have banked AdMSCs in Celltex; written informed consent; highly susceptible to SARS-CoV-2 infections, no terminal stages; no previous COVID-19 history, SARS-CoV-2 RT-PCR or equivalent tests negative; SARS-CoV-2 IgM and IgG negative) , • Three doses of 200 million autologous adipose derived mesenchymal stem cells via intravenously infusion every three days , • Three doses of placebo via intravenously infusion every three days. , • Primary outcomes: Assessment of the total number of AEs/SAEs related and non-related with the medication [Time Frame: 6 months]; Proportion of AEs/SAEs related and non-related with the ASCs infusions as compared to the control group [Time Frame: 6 months]; COVID-19 incidence rates [Time Frame: 6 months] , Not yet recruiting.

Techniques: Clinical Proteomics, Control, Transplantation Assay, Infection

Journal: Clinics

Article Title: Mesenchymal stem cells in lung diseases and their potential use in COVID-19 ARDS: A systematized review

doi: 10.1016/j.clinsp.2023.100237

Figure Lengend Snippet: Unpublished clinical trials on the administration of ASCs in chronic or acute lung diseases.

Article Snippet: Autologous Adipose-derived Stem Cells (AdMSCs) for COVID-19 (2020) , • Phase II randomized, double-blind, placebo-control study conducted in multiple clinic facilities , • 200 participants (> 18 years; male or female; have banked AdMSCs in Celltex; written informed consent; highly susceptible to SARS-CoV-2 infections, no terminal stages; no previous COVID-19 history, SARS-CoV-2 RT-PCR or equivalent tests negative; SARS-CoV-2 IgM and IgG negative) , • Three doses of 200 million autologous adipose derived mesenchymal stem cells via intravenously infusion every three days , • Three doses of placebo via intravenously infusion every three days. , • Primary outcomes: Assessment of the total number of AEs/SAEs related and non-related with the medication [Time Frame: 6 months]; Proportion of AEs/SAEs related and non-related with the ASCs infusions as compared to the control group [Time Frame: 6 months]; COVID-19 incidence rates [Time Frame: 6 months] , Not yet recruiting.

Techniques: Clinical Proteomics, Derivative Assay, Biomarker Discovery, Isolation, Saline, Transplantation Assay, Concentration Assay, Functional Assay, Control, Infection, Reverse Transcription Polymerase Chain Reaction, Activity Assay, Comparison, Injection, Computed Tomography, Sterility, Coagulation